213 related articles for article (PubMed ID: 36054214)
1. Optimal anti-amyloid-beta therapy for Alzheimer's disease via a personalized mathematical model.
Hao W; Lenhart S; Petrella JR
PLoS Comput Biol; 2022 Sep; 18(9):e1010481. PubMed ID: 36054214
[TBL] [Abstract][Full Text] [Related]
2. Personalized Computational Causal Modeling of the Alzheimer Disease Biomarker Cascade.
Petrella JR; Jiang J; Sreeram K; Dalziel S; Doraiswamy PM; Hao W
J Prev Alzheimers Dis; 2024; 11(2):435-444. PubMed ID: 38374750
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US.
Ross EL; Weinberg MS; Arnold SE
JAMA Neurol; 2022 May; 79(5):478-487. PubMed ID: 35344024
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic evaluation of donanemab for the treatment of Alzheimer's.
Song T; Wang Y; Silverglate BD; Grossberg GT
Expert Opin Drug Metab Toxicol; 2024 Jun; 20(6):411-417. PubMed ID: 38758223
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis.
Terao I; Kodama W
Ageing Res Rev; 2024 Feb; 94():102203. PubMed ID: 38253184
[TBL] [Abstract][Full Text] [Related]
6. Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging.
Lowe SL; Duggan Evans C; Shcherbinin S; Cheng YJ; Willis BA; Gueorguieva I; Lo AC; Fleisher AS; Dage JL; Ardayfio P; Aguiar G; Ishibai M; Takaichi G; Chua L; Mullins G; Sims JR
J Prev Alzheimers Dis; 2021; 8(4):414-424. PubMed ID: 34585215
[TBL] [Abstract][Full Text] [Related]
7. Donanemab: Not two without a third.
Kurkinen M
Adv Clin Exp Med; 2023 Oct; 32(10):1085-1087. PubMed ID: 37831471
[TBL] [Abstract][Full Text] [Related]
8. Computational Causal Modeling of the Dynamic Biomarker Cascade in Alzheimer's Disease.
Petrella JR; Hao W; Rao A; Doraiswamy PM
Comput Math Methods Med; 2019; 2019():6216530. PubMed ID: 30863455
[TBL] [Abstract][Full Text] [Related]
9. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects.
Villain N; Planche V; Levy R
Rev Neurol (Paris); 2022 Dec; 178(10):1011-1030. PubMed ID: 36184326
[TBL] [Abstract][Full Text] [Related]
10. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.
Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Liu E; Morris JC; Petersen RC; Saykin AJ; Schmidt ME; Shaw L; Shen L; Siuciak JA; Soares H; Toga AW; Trojanowski JQ;
Alzheimers Dement; 2013 Sep; 9(5):e111-94. PubMed ID: 23932184
[TBL] [Abstract][Full Text] [Related]
11. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
[TBL] [Abstract][Full Text] [Related]
12. Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid-β and tau.
Dickerson BC; Wolk DA;
Front Aging Neurosci; 2013; 5():55. PubMed ID: 24130528
[TBL] [Abstract][Full Text] [Related]
13. The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies: An CTAD Task Force Report.
Delrieu J; Bateman RJ; Touchon J; Sabbagh M; Cummings J
J Prev Alzheimers Dis; 2022; 9(3):393-399. PubMed ID: 35841240
[TBL] [Abstract][Full Text] [Related]
14. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
Podhorna J; Krahnke T; Shear M; Harrison JE;
Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
[TBL] [Abstract][Full Text] [Related]
15. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
[TBL] [Abstract][Full Text] [Related]
16. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment.
Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L;
Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868
[TBL] [Abstract][Full Text] [Related]
17. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.
Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Liu E; Morris JC; Petersen RC; Saykin AJ; Schmidt ME; Shaw L; Siuciak JA; Soares H; Toga AW; Trojanowski JQ;
Alzheimers Dement; 2012 Feb; 8(1 Suppl):S1-68. PubMed ID: 22047634
[TBL] [Abstract][Full Text] [Related]
18. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects.
Trojanowski JQ; Vandeerstichele H; Korecka M; Clark CM; Aisen PS; Petersen RC; Blennow K; Soares H; Simon A; Lewczuk P; Dean R; Siemers E; Potter WZ; Weiner MW; Jack CR; Jagust W; Toga AW; Lee VM; Shaw LM;
Alzheimers Dement; 2010 May; 6(3):230-8. PubMed ID: 20451871
[TBL] [Abstract][Full Text] [Related]
19. Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.
Pittock RR; Aakre JA; Castillo AM; Ramanan VK; Kremers WK; Jack CR; Vemuri P; Lowe VJ; Knopman DS; Petersen RC; Graff-Radford J; Vassilaki M
Neurology; 2023 Nov; 101(19):e1837-e1849. PubMed ID: 37586881
[TBL] [Abstract][Full Text] [Related]
20. Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers.
Da X; Toledo JB; Zee J; Wolk DA; Xie SX; Ou Y; Shacklett A; Parmpi P; Shaw L; Trojanowski JQ; Davatzikos C;
Neuroimage Clin; 2014; 4():164-73. PubMed ID: 24371799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]